Tofogliflozin decreases body fat mass and improves peripheral insulin resistance

Diabetes, Obesity and Metabolism

Volumn 20, Issue 5, 2018, Pages 1311-1315

  Matsuba, Ren ^a   Matsuba, Ikuro ^b   Shimokawa, Mototsugu ^c   Nagai, Yoshio ^a   Tanaka, Yasushi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Matsuba Clinic   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

body composition; DPP 4 inhibitor; insulin resistance; type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; TOFOGLIFLOZIN; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; ANTIOBESITY AGENT; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; GLUCOSIDE; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FAT MASS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID METABOLISM; LIVER FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; ANALYSIS; BLOOD; BODY MASS; BODY WEIGHT LOSS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPEDANCE; METABOLISM; OBESITY;

ADIPOSITY; ANTI-OBESITY AGENTS; BENZHYDRYL COMPOUNDS; BIOMARKERS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; ELECTRIC IMPEDANCE; GLUCOSE CLAMP TECHNIQUE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; OVERWEIGHT; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; WEIGHT LOSS;

EID: 85041594784     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13211     Document Type: Article

References (17)

1. Suzuki M, Takeda M, Kito A, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014;4:e125.
2. Garnock-Jones KP. Saxagliptin/dapagliflozin: a review in type 2 diabetes mellitus. Drugs. 2017;77(3):319-330.
3. Kadowaki T, Inagaki N, Kondo K, et al. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017;19(6):874-882.
4. Sharma MD. Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015;17(7):616-621.
5. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509-514.
6. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214-E223.
7. Emoto M, Morioka T, Yokoyama H, et al. Evaluation of insulin resistance in diabetes: standard protocol for a euglycemic-hyperinsulinemic clamp using an artificial pancreas. In: Inaba M, ed. Musculoskeletal Disease Associated with Diabetes Mellitus. Tokyo, Japan: Springer; 2016:215-235.
8. Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26(1):27-38.
9. Liao X, Wang X, Li H, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitor increases circulating zinc-Α2-glycoprotein levels in patients with type 2 diabetes. Sci Rep. 2016;6:32887.
10. Seino Y, Yabe D, Sasaki T, et al. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: a 52-week, open-label, single-arm study. J Diabetes Investig. 2017. https://doi.org/10.1111/jdi.12694 [Epub ahead of print].
11. Obata A, Kubota N, Kubota T, et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology. 2016;157(3):1029-1042.
12. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92(4):1249-1255.
13. Duez H, Smith AC, Xiao C, et al. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice. Endocrinology. 2009;150(1):56-62.
14. Forst T, Falk A, Andersen G, et al. Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: an exploratory mechanistic study. Diabetes Obes Metab. 2017;19(4):489-495.
15. Wilding JP, Rajeev SP, DeFronzo RA. Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm. Diabetes Care. 2016;39(suppl 2):S154-S164.
16. Ceriello A, Genovese S, Mannucci E, Gronda E. Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol. 2016;15(1):123.
17. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.